- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02933840
Using a Remote Patient Monitoring Alert System to Improve Care
Using a Remote Patient Monitoring Alert System to Improve Care in Geriatric Orthopedic Trauma Patients
Studienübersicht
Status
Intervention / Behandlung
Detaillierte Beschreibung
Geriatric orthopedic trauma patients are a particularly vulnerable cohort due to their age and medical complexity. These patients are often admitted to a floor unit with high physician-to-patient and nurse-to-patient ratios, especially during hours of low staffing intensity (eg, nighttime and weekend hours). As a result, during hours of low staffing intensity the potential for acute deterioration with delayed reaction from the care team is significant. The investigators aim to test the efficacy of a remote patient monitoring platform to reduce adverse events in this population during hours of low staffing intensity. The platform is a software called AlertWatch. It takes laboratory and vital sign data that has been reported in the medical record and determines whether it meets a cut-off value that is concerning for patient deterioration. If the value meets that cut-off, it sends a page to a recipient clinician. The investigators will have a physician trained in intensive care receive these alerts and respond to them by evaluating the patient and, in a consultative capacity, assist the primary team, namely the orthopedic surgery service, in taking care of the patient.
Patients will be randomized to intervention and control arms at the outset of their hospitalization. Patients in the intervention arm will receive standard of care monitoring and the primary team responsible for the care of the patient will remain the orthopedic surgery service, however, in addition, the AlertWatch software will be implemented and the intensive care physician will be involved in the patient's care when there is an alert. Patients in the control arm will receive standard of care monitoring and the orthopedic surgery service will be the primary team responsible. The Investigators will measure whether the intervention reduces adverse events in the study population compared with control patients.
All patients will be enrolled consecutively at the time of admission to the hospital. The AlertWatch platform (510(k) FDA clearance K15335) has the ability to automatically detect whether a patient admitted to a bed on the orthopedic surgery service meets inclusion criteria. The platform will automatically randomize patients into the active arm or the control arm of the study. For patients randomized to the active arm, the platform will provide alert monitoring.
The Investigators will also be enrolling intensive care physicians to participate in this study. Physician participation is optional. In advance of the start of the study, they will be provided information regarding the study and an informed consent document.
The AlertWatch platform has the ability to send an alert when it detects abnormalities, particular trends, or combinations of abnormalities or trends. In this study, the Investigators will use specific threshold values to alert for abnormalities and concerning trends in patient data. When an alert is made, it will be sent to the in-house intensive care physician's regular pager. The page will display the data. Orthopedic interns will continue to monitor for patient data in the standard fashion.
The Investigators will institute a protocol in which an intensive care physician is receiving alerts from AlertWatch during nighttime and weekend hours. The intensivist will: 1.) view the alert, 2.) determine whether any subsequent action is warranted. Subsequent actions may include: 1.) reviewing the patient's chart 2.) visiting the patient and/or his/her nurse 3.) paging the orthopedic surgery team to discuss the patient's situation.
There is an extremely low risk that a patient's safety would be at all threatened in either arm of the study. Patients who are assigned to the intervention arm and the control arm will both receive the standard of care. Intervention arm patients will additionally have the AlertWatch software relaying alerts to designated providers. The software does not create new, previously non-existent data. It relays data that is already available and viewable by all providers in the medical record for the patient. Given the nature of the intervention in this study, the likelihood of any adverse events due to the intervention is extremely low.
Studientyp
Phase
- Unzutreffend
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Admitted to Massachusetts General Hospital or Brigham and Women's Hospital
- Admitted to orthopedic trauma surgery service
- Admitted to a non-ICU bed (patients initially admitted to an ICU and then transferred to the non-ICU bed will be included)
Exclusion Criteria:
- Admitted to service other than orthopedic trauma surgery
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: AlertWatch
Patients will receive standard monitoring and in addition the AlertWatch software will alert the intensive care physician if there is a value that meets criteria for alerting.
The care team will be the orthopedic surgery team in addition to the intensive care physician being involved as a consultant if he/she receives an alert.
|
AlertWatch holds 510(k) FDA clearance K15335.
It is a software program that takes data present in the medical record, including vital signs and laboratory results, and determines whether it meets predetermined thresholds for alerting a clinician.
These thresholds are intended to correlate with signs of acute clinical deterioration in the patient being monitored.
|
Kein Eingriff: No AlertWatch
Patients will receive standard monitoring without the AlertWatch software.
The care team will be the orthopedic surgery team without the intensive care physician being involved as a consultant.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Mortality
Zeitfenster: One year
|
Whether a patient experiences death during their hospitalization.
|
One year
|
Transfer to the ICU
Zeitfenster: One year
|
Whether the patient is transferred from a floor unit to the intensive care unit during their hospitalization.
|
One year
|
Cardiac arrest
Zeitfenster: One year
|
Whether the patient experiences a cardiac arrest during their hospitalization.
|
One year
|
Rapid response team called
Zeitfenster: One year
|
Whether the a rapid response team is called to assess the patient during their hospitalization.
|
One year
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Time to ordering of blood
Zeitfenster: One year
|
Time from hemoglobin < 7 to when blood product is ordered for patient during their hospitalization.
|
One year
|
Time to ordering of fluids or vasopressors
Zeitfenster: One year
|
Time from systolic blood pressure<80, diastolic<40 to when fluids or vasopressors are ordered for patient during their hospitalization.
|
One year
|
Time to ordering of diuretics, NIPPV, or intubation
Zeitfenster: One year
|
Time from oxygen saturation<90% to when diuretics, NIPPV, or intubation are ordered for patient during their hospitalization.
|
One year
|
Time to ordering of nodal blocking agent
Zeitfenster: One year
|
Time from heart rate >130 to when a nodal blocking agent (beta blocker, calcium channel blocker, digoxin, or amiodarone) is ordered for patient during their hospitalization.
|
One year
|
Time to ordering of insulin
Zeitfenster: One year
|
Time from glucose >350 or <60 to when insulin is ordered for patient during their hospitalization.
|
One year
|
Time to ordering of diuretics or insulin/D50
Zeitfenster: One year
|
Time from potassium>6 to when diuretics or insulin/D50 is ordered for patient during their hospitalization.
|
One year
|
Time to ordering of appropriate fluids
Zeitfenster: One year
|
Time from sodium>145 or sodium<130 to when appropriate fluids are ordered for patient during their hospitalization.
|
One year
|
Time to ordering to discontinue foley catheter
Zeitfenster: One year
|
Time from foley catheter insertion to foley catheter discontinuation during their hospitalization.
|
One year
|
Time to improvement of hemoglobin
Zeitfenster: One year
|
Time from hemoglobin <7 to hemoglobin>7
|
One year
|
Time to improvement of blood pressure
Zeitfenster: One year
|
Time from systolic blood pressure<80, diastolic<40 to systolic blood pressure>80, diastolic>40
|
One year
|
Time to improvement of oxygen saturation
Zeitfenster: One year
|
Time from oxygen saturation to <90% to oxygen saturation >90%
|
One year
|
Time to improvement of heart rate
Zeitfenster: One year
|
Time from heart rate >130 to heart rate <130
|
One year
|
Time to improvement of glucose
Zeitfenster: One year
|
Time from glucose >350 or <60 to glucose <350, >60
|
One year
|
Time to improvement of potassium
Zeitfenster: One year
|
Time from potassium >6 to potassium to <6
|
One year
|
Time to improvement of sodium
Zeitfenster: One year
|
Time from sodium >145 or <130 to sodium <145, >130
|
One year
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Aalok V Agarwala, MD, MBA, Massachusetts General Hospital
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 2016P002227
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur AlertWatch
-
Washington University School of MedicineAbgeschlossenWahloperationVereinigte Staaten